Kathleen M Metters
Dr Kathleen Metters joined the Board of Directors in June 2017 and appointed chair in October 2023. Kathleen brings more than 25 years of experience in the discovery and development of novel therapies for treatment of serious diseases. She was formerly the Senior Vice President and Head of Worldwide Basic Research for Merck & Co. with oversight of all the company’s global research projects. In a subsequent role at Merck &Co. She led work on External Discovery and Preclinical Sciences.
Kathleen was President and CEO of biopharmaceutical company Lycera Corp and is currently an independent consultant and senior advisor for Bridge Medicines. She is currently a non-executive board member of HemoShear Therapeutics, LLC and Aslan Pharmaceuticals Ltd.
Kathleen graduated with a B.S. in biochemistry from the University of Manchester Institute for Science and Technology, and a Ph.D. from Imperial College of Science and Technology in London.
Dr Metters is a member of the Company's Scientific Advisory Board and is a member of the Audit Committee.